PLAUR and COVID-19: Results of Anakinra (an Ab against the IL-1 receptor alpha) on the improvement of acute respiratory distress syndrome in COVID-19 patients vary from showing no effect (52) to being effective in a subgroup of patients with increased soluble uPAR (s-uPAR) levels (32, 53).